Celltrion's Truxima leads U.S. prescription market in Feb.
Story summarySEOUL, April 7 (Yonhap) -- Celltrion Inc., a leading South Korean biopharmaceutical company, said Tuesday its biosimilar Truxima, used to treat blood cancers, claimed the largest share of prescriptions in the United States in February.
Read at South KoreaOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.